Back to search results

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer · Endometrial Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • City of Hope Comprehensive Cancer Center, Duarte, California, United States

  • The City of Hope Orange County Lennar Foundation Cancer Center, Irvine, California, United States

  • Chao Family Comprehensive Cancer Center, Orange, California, United States

  • H. Lee Moffitt Cancer Center, Tampa, Florida, United States

  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, United States

  • University of Chicago Medical Center, Chicago, Illinois, United States

  • Massachusetts General Hospital, Boston, Massachusetts, United States

  • Dana Farber Cancer Institute Brookline Avenue, Boston, Massachusetts, United States

  • Karmanos Cancer Institute, Detroit, Michigan, United States

  • Memorial Sloan Kettering Cancer Center, New York, New York, United States

  • The Ohio State University Wexner Medical Center, Columbus, Ohio, United States

  • Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, United States

  • Seattle Cancer Care Alliance at South Lake Union - G3630, Seattle, Washington, United States

  • Universitair Ziekenhuis Leuven, Leuven, Vlaams-Brabant, Belgium

  • Hopital Lyon Sud, Pierre-Bénite, Auvergne-Rhône, France

  • Centre Georges Francois Leclerc, Dijon, Bourgogne-Franche-Comté, France

  • Institut Bergonie, Bordeaux, New Aquitaine, France

  • Centre Francois Baclesse (CFB), Caen, Normandy, France

  • Institut Gustave Roussy, Villejuif, France

  • Hospital Clinico Universitario Santiago de Compostela, Santiago de Compostela, A Coruna, Spain

  • Institut Catala dOncologia Girona, Girona, Spain

  • Ciudad Universitaria, Madrid, Spain

  • Hospital Universitario Fundacion Jimenez, Madrid, Spain

  • Hospital Universitario 12 de Octubre Universidad Complutense de Madrid UCM, Madrid, Spain

Study leads

  • Clinical Trial Management

    Study Director

    Regeneron Pharmaceuticals

View source on ClinicalTrials.gov(opens in a new tab)